Bionime Corporation (4737) Fair Value & Analysis
Healthcare · TW · Market cap 4.2B TWD
Fair value as of: Jun 24, 2026
Analysis
Bionime Corporation (4737) currently trades at 57.10 TWD, while our model-based Fair Value estimate is 23.03 TWD — implying the stock looks roughly 59.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Belarus, Algeria, the United Arab Emirates, Egypt, and internationally. The company manufactures and sells blood glucose meters and test strips to medical equipment companies, pharmacies, and hospitals, as well as offering blood glucose monitoring devices and systems under the RIGHTEST brand; a continuous glucose monitoring system under the iFree CGM brand; and medical blood glucose management systems. It is also involved in the provision of biotechnology services; drug testing; examination of pharmaceutical products; and the sale of precision instruments. The company also provides wholesale medical devices, biotechnology services, pharmaceutical testing, and wholesale of precision instruments. Bionime Corporation was incorporated in 2003 and is based in Taichung, Taiwan.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Bionime Corporation (4737) undervalued?
What is the fair value of 4737?
What is the quality score of 4737?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.